79 related articles for article (PubMed ID: 21692050)
1. Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.
Shariat SF; Savage C; Chromecki TF; Sun M; Scherr DS; Lee RK; Lughezzani G; Remzi M; Marberger MJ; Karakiewicz PI; Vickers AJ
Cancer; 2011 Jul; 117(13):2892-7. PubMed ID: 21692050
[TBL] [Abstract][Full Text] [Related]
2. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.
Kim PH; Sukhu R; Cordon BH; Sfakianos JP; Sjoberg DD; Hakimi AA; Dalbagni G; Lin O; Herr HW
BJU Int; 2014 Sep; 114(3):354-9. PubMed ID: 24128299
[TBL] [Abstract][Full Text] [Related]
3. Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer.
Krishnatry R; Maitre P; Kumar A; Telkhade T; Bakshi G; Prakash G; Pal M; Joshi A; Menon S; Murthy V
Cancer Med; 2023 May; 12(10):11305-11314. PubMed ID: 36965102
[TBL] [Abstract][Full Text] [Related]
4. Nuclear matrix protein 22 in bladder cancer.
Cheng K; Wan S; Chen SY; Yang JW; Wang HL; Xu CH; Qiao SH; Yang L
Clin Chim Acta; 2024 May; 560():119718. PubMed ID: 38718852
[TBL] [Abstract][Full Text] [Related]
5. Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer.
Vedeld HM; Pharo H; Sørbø AK; Brandt-Winge S; Five MB; Jeanmougin M; Guldberg P; Wahlqvist R; Lind GE
Mol Oncol; 2024 May; ():. PubMed ID: 38720532
[TBL] [Abstract][Full Text] [Related]
6. Surveillance for Nonmuscle Invasive Bladder Cancer: Identifying the Point of Diminishing Returns.
Ranti D; Dey L; Bieber C; Grauer R; Rich J; Rosenzweig S; Koskela LR; Steineck G; Hosseini A; Egevad L; Patrakka J; Attalla K; Wiklund P; Sfakianos J; Waingankar N
Urology; 2023 Nov; 181():84-91. PubMed ID: 37604253
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.
Bell MD; Yafi FA; Brimo F; Steinberg J; Aprikian AG; Tanguay S; Kassouf W
World J Urol; 2016 Oct; 34(10):1405-9. PubMed ID: 26906030
[TBL] [Abstract][Full Text] [Related]
8. Quantifying Clinicians' Diagnostic Uncertainty When Making Initial Treatment Decisions for Microbial Keratitis.
Hicks PM; Singh K; Prajna NV; Lu MC; Niziol LM; Greenwald MF; Verkade A; Amescua G; Farsiu S; Woodward MA;
Cornea; 2023 Nov; 42(11):1408-1413. PubMed ID: 36256441
[TBL] [Abstract][Full Text] [Related]
9. Unbiased enrichment of urine exfoliated cells on nanostructured substrates for sensitive detection of urothelial tumor cells.
Wang X; Gu Y; Zhang S; Li G; Liu T; Wang T; Qin H; Jiang B; Zhu L; Li Y; Lei H; Li M; Zhang Q; Yang R; Fang F; Guo H
Cancer Med; 2020 Jan; 9(1):290-301. PubMed ID: 31709750
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
[TBL] [Abstract][Full Text] [Related]
11. New Insights in Bladder Cancer Diagnosis: Urinary miRNAs and Proteins.
Amuran GG; Eyuboglu IP; Tinay I; Akkiprik M
Med Sci (Basel); 2018 Dec; 6(4):. PubMed ID: 30544619
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic biomarkers in non-muscle invasive bladder cancer.
Faiena I; Rosser CJ; Chamie K; Furuya H
World J Urol; 2019 Oct; 37(10):2009-2016. PubMed ID: 30467596
[TBL] [Abstract][Full Text] [Related]
13. Current Use and Promise of Urinary Markers for Urothelial Cancer.
Tabayoyong W; Kamat AM
Curr Urol Rep; 2018 Oct; 19(12):96. PubMed ID: 30328534
[TBL] [Abstract][Full Text] [Related]
14. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.
Soria F; Droller MJ; Lotan Y; Gontero P; D'Andrea D; Gust KM; Rouprêt M; Babjuk M; Palou J; Shariat SF
World J Urol; 2018 Dec; 36(12):1981-1995. PubMed ID: 29931526
[TBL] [Abstract][Full Text] [Related]
15. Unmasking molecular profiles of bladder cancer.
Piao XM; Byun YJ; Kim WJ; Kim J
Investig Clin Urol; 2018 Mar; 59(2):72-82. PubMed ID: 29520382
[TBL] [Abstract][Full Text] [Related]
16. The contemporary role and impact of urine-based biomarkers in bladder cancer.
Duquesne I; Weisbach L; Aziz A; Kluth LA; Xylinas E;
Transl Androl Urol; 2017 Dec; 6(6):1031-1042. PubMed ID: 29354490
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of a Machine Learning Model with EuroSCORE II in Predicting Mortality after Elective Cardiac Surgery: A Decision Curve Analysis.
Allyn J; Allou N; Augustin P; Philip I; Martinet O; Belghiti M; Provenchere S; Montravers P; Ferdynus C
PLoS One; 2017; 12(1):e0169772. PubMed ID: 28060903
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for precision medicine in bladder cancer.
Kojima T; Kawai K; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2017 Apr; 22(2):207-213. PubMed ID: 27896485
[TBL] [Abstract][Full Text] [Related]
19. Simplified Acute Physiology Score II as Predictor of Mortality in Intensive Care Units: A Decision Curve Analysis.
Allyn J; Ferdynus C; Bohrer M; Dalban C; Valance D; Allou N
PLoS One; 2016; 11(10):e0164828. PubMed ID: 27741304
[TBL] [Abstract][Full Text] [Related]
20. Urothelial Bladder Cancer Urinary Biomarkers.
Noon AP; Zlotta AR
EJIFCC; 2014 Apr; 25(1):99-114. PubMed ID: 27683459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
